Moxonitex pills 200mcg, 14pcs

Composition

Tablets covered with a film-coated light pink color, round, biconvex.

1 tab. moxonidine 200 mcg

Excipients:

lactose monohydrate-94.5 mg,

povidone K 25-2 mg,

crospovidone-3 mg,

magnesium stearate-0.3 mg.

Composition of the film shell:

 opadray Y 1 7000 – 3.498 mg (titanium dioxide-1.093 mg, hypromellose-2.186 mg, macrogol 400-0.219 mg), iron oxide red dye-0.002 mg

Pharmacological action

Selective agonist of imidazoline receptors. Antihypertensive medication

Indications

-arterial hypertension.

Contraindications

— a history of angioedema;

— SSSU or sinoatrial block;

— AV-block II and III degree;

— severe bradycardia (less than 50 beats/min at rest);

— severe heart rhythm disorders;

— chronic heart failure (III-IV functional class NYHA classification);

— unstable angina;

— severe hepatic impairment;

renal failure severe (CC less than 30 ml/min, serum creatinine more than 160 µmol/l);

— age up to 18 years;

— lactation period;

— galactose intolerance, lactase deficiency or malabsorption syndrome glucose-galactose;

— hypersensitivity to moxonidine or any other component of the drug.

With caution and under the supervision of a physician should use the drug in patients with recent myocardial infarction, or when violations of the peripheral circulation (intermittent claudication, Raynaud’s syndrome); in patients with moderately severe renal impairment (CC 30-60 ml/min; serum creatinine 105-160 µmol/l), with impaired liver function, pregnancy, depression, glaucoma, epilepsy, Parkinson’s disease.

Side effects

Determination of the frequency of adverse reactions: common (≥1%), rare (0.01%-0.1%), sometimes (

From the cardiovascular system: rarely-symptoms of vasodilation; sometimes-a marked decrease in blood pressure, syncopal states, Raynaud’s syndrome, peripheral edema.

From the central nervous system: often – dizziness, headache, drowsiness, fatigue, sleep disorders; sometimes-paresthesia, depression, anxiety.

From the digestive system: often – dryness of the oral mucosa, nausea, anorexia, constipation.

From the genitourinary system: sometimes-urinary retention or incontinence, impotence and / or decreased libido.

From the side of the sensory organ: sometimes-dry eyes that cause itching or burning sensation.

Allergic reactions: sometimes – urticaria, pruritus, exanthema, angioedema.

Other services: sometimes-gynecomastia, parotid gland soreness.

Interaction

When moxonidine is co-administered with other antihypertensive agents, the effect is mutually enhanced.

Beta-blockers increase bradycardia, the severity of negative ino-and dromotropic effects.

Moxonidine enhances the hypotensive effect of ethanol, sedatives, slow calcium channel blockers (dihydropyridine derivatives).

Do not use moxonidine concomitantly with tricyclic antidepressants.

TOlasoline dose-dependently reduces the hypotensive effect of moxonidine.

How to take, course of use and dosage

Moxonitex is prescribed orally, regardless of food intake, with a sufficient amount of liquid. The dosage regimen is selected individually.

The initial dose is 200 mcg in the morning. If the therapeutic effect is insufficient, the dose is increased to 400 mcg/day once or in 2 doses after 3 weeks. The maximum daily dose is 600 mcg, the maximum single dose is 400 mcg.

In patients with moderate renal impairment (creatinine clearance 30-60 ml / min) a single dose should not exceed 200 mcg, the maximum daily dose is 400 mcg.

Overdose

Symptoms: headache, marked decrease in blood pressure, bradycardia, palpitations, weakness, drowsiness, dryness of the oral mucosa; rarely-vomiting and epigastric pain. Paradoxical arterial hypertension and hyperglycemia are potentially possible.

Treatment: symptomatic. There is no specific antidote. With a pronounced decrease in blood pressure, it is recommended to restore the BCC by introducing fluid. Alpha-adrenergic antagonists can reduce or eliminate transient arterial hypertension in case of overdose with moxonidine.

Special instructions

During treatment, regular monitoring of blood pressure, heart rate and ECG is required.

If it is necessary to cancel the simultaneous use of beta-blockers and Moxonitex, the beta-blockers are first canceled and only a few days later – Moxonitex. Stop taking Moxonitex gradually.

Influence on the ability to drive motor vehicles and manage mechanisms

The effect of Moxonitex on the ability to drive vehicles or operate machinery has not been studied. Taking into account the possible occurrence of dizziness and drowsiness, patients should exercise caution when engaging in potentially dangerous activities, such as driving vehicles or operating equipment that require increased concentration of attention.

Active ingredient

Moxonidine

Conditions of release from pharmacies

By prescription

Dosage form

Tablets

Description

For pregnant women as prescribed by a doctor, For adults as prescribed by a doctor

Indications

Hypertension